Application of a methicillin-resistant  risk score for community-onset pneumonia patients and outcomes with initial treatment by unknown
RESEARCH ARTICLE Open Access
Application of a methicillin-resistant
Staphylococcus aureus risk score for
community-onset pneumonia patients and
outcomes with initial treatment
Besu F. Teshome1,2,3, Grace C. Lee2,3, Kelly R. Reveles2,3, Russell T. Attridge4,5, Jim Koeller2,3, Chen-pin Wang6,
Eric M. Mortensen7,8 and Christopher R. Frei2,3*
Abstract
Background: Community-onset (CO) methicillin-resistant Staphylococcus aureus (MRSA) pneumonia is an evolving
problem, and there is a great need for a reliable method to assess MRSA risk at hospital admission. A new MRSA
prediction score classifies CO-pneumonia patients into low, medium, and high-risk groups based on objective criteria
available at baseline. Our objective was to assess the effect of initial MRSA therapy on mortality in these three risk groups.
Methods: We conducted a retrospective cohort study using data from the Veterans Health Administration (VHA).
Patients were included if they were hospitalized with pneumonia and received antibiotics within the first 48 h of
admission. They were stratified into MRSA therapy and no MRSA therapy treatment arms based on antibiotics received in
the first 48 h. Multivariable logistic regression was used to adjust for potential confounders.
Results: A total of 80,330 patients met inclusion criteria, of which 36 % received MRSA therapy and 64 % did not receive
MRSA therapy. The majority of patients were classified as either low (51 %) or medium (47 %) risk, with only 2 % classified
as high-risk. Multivariable logistic regression analysis demonstrated that initial MRSA therapy was associated with a lower
30-day mortality in the high-risk group (adjusted odds ratio 0.57; 95 % confidence interval 0.42–0.77). Initial MRSA therapy
was not beneficial in the low or medium-risk groups.
Conclusions: This study demonstrated improved survival with initial MRSA therapy in high-risk CO-pneumonia patients.
The MRSA risk score might help spare MRSA therapy for only those patients who are likely to benefit.
Background
Pneumonia is a major cause of mortality in the United
States, with a reported 49,597 deaths in 2010 [1].
Community-onset (CO) pneumonia is defined as pneumo-
nia that occurs in the community and up to 48 h into hos-
pital admission. It encompasses both community-acquired
pneumonia (CAP) and healthcare-associated pneumonia
(HCAP). Importantly, HCAP patients are at increased risk
of methicillin-resistant Staphylococcus aureus (MRSA)
pneumonia [2–4]. Lastly, MRSA pneumonia is associated
with greater morbidity and mortality than pneumonia
caused by other etiologies, possibly due to the virulent and
resistant nature of the MRSA pathogen [4]. MRSA accounts
for 20–40 % of pneumonia cases that occur after 48 h into
hospital admission and 2–25 % of CO cases overall [4–8].
Previous studies have demonstrated that rapid initiation of
appropriate antibiotic therapy is associated with improved
survival in hospitalized patients with infections [9, 10]; there-
fore, there is a great need for a reliable method to assess
CO-MRSA pneumonia risk at admission. Guidelines recom-
mend use of the HCAP criteria to determine need for em-
piric MRSA therapy, but this definition lacks specificity for
CO-MRSA pneumonia and may lead to overuse of broad-
spectrum antibiotic therapy [2, 11]. Finally, prior studies
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have demonstrated that when HCAP patients received
guideline-recommended, broad-spectrum therapy (including
MRSA therapy), outcomes were no better than when similar
patients received alternative antibiotics [12, 13].
Guidance is needed for clinicians to identify those
CO-pneumonia patients who might benefit from empiric
MRSA therapy.
Recently, Shorr et al. derived a clinical prediction score
that stratified patients with CO-pneumonia by their MRSA
risk [14]. The risk score consisted of eight variables. Two
points were assigned for recent hospitalization or intensive
care unit (ICU) admission and one point was assigned for
each of the following: age <30 or >79 years, prior intraven-
ous (IV) antibiotics in last 30 days, dementia, cardiovascu-
lar disease, female with diabetes, or recent exposure to a
nursing home, long-term care facility, or skilled nursing
facility. The total score ranged from 0 to 10, and patients
were stratified into low (0–1), medium (2–5), and high
(6–10) risk groups. The CO-MRSA pneumonia prevalence
increased from <10 % in the low-risk group to >30 % in the
high-risk group. The authors concluded that this risk score
could help identify those patients at low risk of MRSA, for
which MRSA therapy could be spared. They postulated
that patients in the high-risk group might benefit from
MRSA therapy [14]; however, this has yet to be proven.
The new MRSA risk score could help guide empiric
MRSA therapy; however, studies are needed to deter-
mine which, if any, of the MRSA risk groups benefit
from such therapy. Our primary objective was to com-
pare the effect of MRSA therapy on 30-day patient mor-
tality among CO-pneumonia patients in the three MRSA
risk groups (low, medium, and high-risk). Our secondary
objective was to determine the association of MRSA risk
score with 30-day mortality.
Methods
This study used administrative data from the Veterans
Health Administration (VHA) database. Description of the
methods used to build this database have been previously
reported [12, 15, 16]. In brief, we performed a retrospect-
ive, population-based cohort study using administrative
data from the VHA system between fiscal years 2002 and
2007. These data are from over 150 VHA hospitals and
850 VHA outpatient clinics. Data for this study were
obtained from the VHA electronic medical record system
that includes administrative, clinical, laboratory, and phar-
macy data. The Institutional Review Board of the Univer-
sity of Texas Health Science Center at San Antonio and
the South Texas Veterans Health Care System Research
and Development committee approved this study.
Patients were included if they were ≥65 years of age and
had either a primary discharge diagnosis of pneumonia/
influenza (International Classification of Diseases,
Ninth Revision, Clinical Modification [ICD-9-CM]
codes 480.0–483.99 or 485–487) (Additional file 1) or a
secondary discharge diagnosis of pneumonia/influenza
plus a primary diagnosis of respiratory failure (ICD-9-CM
code 518.81), or sepsis (ICD-9-CM code 038.xx) in fiscal
years 2002–2007. If a patient was admitted more than once
during the study period, only the first hospitalization was
included. Patients were excluded if they did not receive
antimicrobial therapy within the first 48 h of admission.
Baseline demographics were recorded at the time of ad-
mission. Antibiotic use was recorded for the first 48 h of
admission. Comorbid conditions were determined using
ICD-9-CM codes from outpatient and inpatient care in
accordance with the Charlson comorbidity scoring system
[17, 18]. Organ failure included acute and chronic condi-
tions (Additional file 1).
The MRSA risk score variables were defined as: patient
age >79 years, hospitalization in the past 90 days, (ICU)
admission, outpatient (IV) antibiotic therapy within the
past 90 days, nursing home resident in the last 90 days,
cerebrovascular disease, dementia, and female with dia-
betes mellitus. These were based on the MRSA risk score
developed by Shorr et al. and modified for our database.
All of our patients were ≥65 years of age, so the criteria
related to age <30 years did not apply. Also, recent
hospitalization was not limited to stays of ≥2 days, prior IV
antibiotic therapy was extended from 30 to 90 days, and
ICU admission was not limited to on or before index cul-
ture [14]. Each variable contributed one point to the risk
score, except for hospitalization in the past 90 days and
ICU admission, for which each contributed two points. Pa-
tients were stratified into three risk groups based on their
risk score: low (0–1), medium (2–5), and high (6–10) [14].
Patients who met study criteria were divided into two
groups: the “MRSA therapy” group and the “no MRSA
therapy” group. Initial MRSA therapy was defined as the
receipt of either vancomycin or linezolid within the first
48 hours of admission. Patients were also categorized
based on the receipt of guideline-concordant community-
acquired pneumonia (GC-CAP) therapy [19], pseudomo-
nal therapy, and atypical therapy (Table 1). Pneumonia
pathogens, including MRSA, were identified using ICD-9-
CM codes (Additional file 1).
All-cause 30-day patient mortality was the primary
study outcome. Previous research has demonstrated
that 30-day mortality is more closely associated with
pneumonia-related mortality, as compared to 60-day or
90-day mortality [20]. Mortality was assessed using the
VHA vital status file, which has been demonstrated to
have 98 % exact agreement with the National Death
Index, the “gold standard” to determine mortality [21].
Statistical analyses
All statistical analyses were conducted using JMP 10.0®
(SAS Corp, Cary, NC). Chi-square or Fisher’s exact test
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were used to compare categorical variables between study
arms (Table 2). Continuous variables were compared
using the Wilcoxon Rank Sum test (Table 2). For bivariate
statistical tests, we defined significance as a two-tailed
alpha ≤0.0001 to avoid spurious associations in this large
patient cohort.
Separate multivariable logistic regression models were
constructed to examine if MRSA therapy was associated
with 30-day mortality in the overall population and each
of the three MRSA risk groups. The dependent variable
was 30-day patient mortality, and the independent variable
was MRSA therapy versus no MRSA therapy. Covariates
included all unbalanced characteristics that were signifi-
cant in the bivariate analysis comparing 30-day mortality
versus no 30-day mortality (Additional file 2). Finally,
MRSA culture-positivity was also entered into the model.
Adjusted odds ratios (aORs) and 95 % confidence intervals
(95 % CIs) were calculated; those 95 % CIs that did not
cross one were considered to be statistically significant.
A few of the variables were excluded from the model
because of collinearity. Collinearity was determined
through theoretical relations for select variables. For in-
stance, most patients on hemodialysis also had renal fail-
ure; therefore, hemodialysis was chosen for the model.
Likewise, most patients who had diabetes mellitus also
received anti-diabetic medications; therefore, the anti-
diabetic medications variable was chosen for the model.
The Charlson score and the “any organ failure” variables
were excluded from the model because individual comor-
bidities and organ failures were already included in the
model. Individual MRSA risk score variables were also ex-
cluded from the model because we ran separate multivari-
able models for the three risk groups, and these individual
characteristics were used to define those risk groups.
The final list of 25 covariates included: patient age, race,
Hispanic ethnicity, myocardial infarction, heart failure,
chronic obstructive pulmonary disease (COPD), liver
disease, renal disease, neoplastic disease, cardiovascular
medications, anti-diabetic medications, inhaled cortico-
steroids, pulmonary medications, vasopressors, invasive
and non-invasive mechanical ventilation, respiratory failure,
cardiovascular failure, neurological failure, renal failure,
hematological failure, hepatic failure, GC-CAP therapy,




Baseline patient characteristics are shown in Table 2. A
total of 80,330 patients met inclusion criteria, with 36 % in
the MRSA therapy group and 64 % in the no MRSA ther-
apy group. Patients were predominately elderly (median
age 78 years), white (81 %) men (98 %). Age >79 was the
most common MRSA risk factor (44 %), followed by
hospitalization in the past 90 days (28 %) and ICU admis-
sion (21 %). There were very few women with diabetes
mellitus (0.4 %) in this population. The median MRSA risk
score was 1 (interquartile range [IQR] 0–3). The majority
of patients were classified as either low (51 %) or medium
(47 %) risk, with only 2 % classified as high-risk. None of
the patients scored above an 8 on the MRSA risk score.
The median (IQR) Charlson score was 2 (1–4), and
common comorbidities included COPD (49 %), diabetes
(31 %), heart failure (26 %), and neoplastic disease (25 %).
The most commonly used medications within 90 days
prior to admission included cardiovascular medications
(67 %) and pulmonary medications (35 %). Organ failure
occurred in 32 % of patients. Finally, most patients re-
ceived atypical (75 %) and GC-CAP (64 %) therapy.
Baseline characteristics
Patient age and sex were similar between MRSA therapy
and no MRSA therapy groups. A lower proportion of white
patients received MRSA therapy, while higher proportions
of black and Hispanic patients received MRSA therapy.
Charlson scores were higher in the MRSA therapy group
and these patients had a higher prevalence of heart failure,
renal disease, diabetes, and neoplastic disease. In addition,
the MRSA therapy group had a higher prevalence of vaso-
pressor use, mechanical ventilation, hemodialysis, organ





Ward patients ICU patients
• Beta-lactama plus (macrolideb
or doxycycline)
• Beta-lactama plus (macrolideb or
doxycycline)
• Respiratory fluoroquinolonec • Beta-lactama plus respiratory
fluoroquinolonec
Pseudomonal therapy
• Antipseudomonal beta-lactamd plus antipseudomonal
fluoroquinolonee





CAP Community-acquired pneumonia, ICU Intensive care unit
aBeta-lactam includes cefotaxime, ceftriaxone, ampicillin-sulbactam, ertapenum,
or aztreonam
bMacrolide includes azithromycin, clarithromycin, or erythromycin
cRespiratory fluoroquinolone includes moxifloxacin, levofloxacin, or gatifloxacin
dAntipseudomonal beta-lactam includes cefepime, ceftazidime, imipenem-cilastatin,
meropenem, piperacillin-tazobactam, or ticarcillin-clavulanate, aztreonam
eAntipseudomonal fluoroquinolone includes ciprofloxacin or levofloxacin
fAminoglycoside includes gentamicin, tobramycin, or amikacin
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Table 2 Baseline characteristics grouped by MRSA therapy
Overall (n = 80,330) MRSA therapy (n = 29,254) No MRSA therapy (n = 51,076) P-value*
Patient age (years), median (IQR) 78 (72–83) 78 (73–83) 77 (72–83) 0.1016
Male, % 98.3 98.3 98.3 0.6847
Race, %
White 81.1 79.1 82.3 < 0.0001
Black 13.1 15.4 11.7 < 0.0001
Other 5.8 5.5 6.0 < 0.0001
Hispanic ethnicity, % 7.0 8.0 6.4 < 0.0001
MRSA risk score variables, % (1 point, unless noted)
Age >79 43.8 44.0 43.7 0.3867
Hospitalization in the past 90 days (2 points) 27.8 33.7 24.5 < 0.0001
Intensive care unit admission (2 points) 21.1 29.3 16.4 < 0.0001
Outpatient IV antibiotic therapy in past 90 days 4.9 5.3 4.7 0.0001
Nursing home resident in last 90 days 1.0 1.1 0.9 0.0028
Cerebrovascular disease 18.1 19.6 17.3 < 0.0001
Dementia 5.2 5.8 4.9 < 0.0001
Female with diabetes mellitus 0.4 0.4 0.4 0.8129
MRSA risk score, median (IQR) 1 (0–3) 2 (1–3) 1 (0–2) < 0.0001
Low (0–1), % 51.4 41.6 57.0 < 0.0001
Medium (2–5), % 47.3 56.4 42.1 < 0.0001
High (6–10), % 1.3 2.1 0.9 < 0.0001
Charlson comorbidity score, median (IQR) 2 (1–4) 3 (1–4) 2 (1–4) < 0.0001
Comorbid conditions, %
Myocardial infarction 7.2 7.6 7.0 0.0020
Heart failure 25.9 27.0 25.3 < 0.0001
Chronic obstructive pulmonary disease 48.7 45.5 50.5 < 0.0001
Liver disease 1.3 1.5 1.2 0.0035
Renal disease 14.1 17.2 12.3 < 0.0001
Diabetes 30.5 31.8 29.8 < 0.0001
Neoplastic disease 25.2 26.2 24.7 < 0.0001
HIV/AIDS 0.2 0.3 0.2 0.0961
Medication use within 90 days, %
Cardiovascular medications 66.5 64.9 67.3 < 0.0001
Anti-diabetic medications 22.2 22.6 22.1 0.0852
Inhaled corticosteroids 21.1 18.9 22.4 < 0.0001
Systemic corticosteroids a 22.2 21.8 22.5 0.0217
Pulmonary medications 34.8 31.4 36.8 < 0.0001
Vasopressors, % 10.2 15.2 7.2 < 0.0001
Invasive mechanical ventilation, % 11.1 16.3 8.2 < 0.0001
Noninvasive mechanical ventilation, % 4.0 5.7 3.1 < 0.0001
Hemodialysis, % 18.3 22.7 15.7 < 0.0001
Organ failure, %
Any organ failure, % 32.2 41.8 26.7 < 0.0001
Respiratory 14.4 19.4 11.5 < 0.0001
Cardiovascular 9.7 13.0 7.8 < 0.0001
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failure, GC-CAP therapy, pseudomonal therapy, and atyp-
ical therapy. In contrast, the no MRSA therapy group had
a higher prevalence of COPD and were more likely to re-
ceive cardiovascular medications, inhaled corticosteroids,
and pulmonary medications in the last 90 days.
Bacterial pathogens
The prevalence of bacterial pathogens is shown in Table 3.
Staphylococcus aureus was the most commonly isolated
pathogen and the majority of those isolates were MRSA.
Streptococcus pneumoniae was the second most common
pathogen. The MRSA therapy group had more patients
who were culture-positive and had higher rates of Staphylo-
coccus aureus, MRSA, Pseudomonas spp., and most other
gram-negative pathogens, except for Haemophilus influenzae.
Patient mortality
The overall 30-day patient mortality rate was 20 %, and the
unadjusted 30-day mortality increased from the low (11 %),
medium (27 %), and high (48 %) risk groups (p <0.0001). In
addition, an increase in unadjusted 30-day mortality was
observed with each additional point of the MRSA risk
score (Fig. 1). Unadjusted 30-day mortality was higher
among patients who received MRSA therapy in the low-
Table 2 Baseline characteristics grouped by MRSA therapy (Continued)
Neurological 2.5 3.3 2.0 < 0.0001
Renal 20.1 26.8 16.2 < 0.0001
Hematologic 4.1 5.5 3.3 < 0.0001
Hepatic 0.7 0.9 0.6 < 0.0001
Antibiotic therapy, %
Guideline-concordant CAP therapy 64.1 64.9 63.6 0.0001
Pseudomonal therapy 17.5 31.1 9.7 < 0.0001
Atypical therapy 75.2 83.6 70.5 < 0.0001
MRSA Methicillin-resistant Staphylococcus aureus, IQR Interquartile range, IV Intravenous, HIV/AIDS Human immunodeficiency virus/acquired immunodeficiency
syndrome, CAP Community-acquired pneumonia
a Includes oral and/or injectable corticosteroids
* Comparison between “MRSA therapy” versus “no MRSA therapy” groups
Table 3 Bacterial pathogen distribution grouped by MRSA therapy
Overall (n = 80,330) MRSA therapy (n = 29,254) No MRSA therapy (n = 51,076) P-value*
Organism identified, % 10.3 13.9 8.2 < 0.0001
Single organism identified 9.3 12.1 7.7 < 0.0001
Multiple organisms identified 1.0 1.9 0.5 < 0.0001
Gram-positive pathogens, %
Streptococcus pneumoniae 2.8 2.7 2.9 0.0571
Streptococcus, other 0.4 0.5 0.4 0.0270
Staphylococcus aureus 5.1 8.7 3.1 < 0.0001
MRSA 3.3 5.1 2.3 < 0.0001
Gram-negative pathogens, %
Klebsiella pneumoniae 0.7 1.0 0.6 < 0.0001
Pseudomonas spp. 1.5 1.9 1.2 < 0.0001
Haemophilus influenzae 0.8 0.5 0.9 < 0.0001
Escherichia coli 0.2 0.4 0.2 < 0.0001
Other gram-negatives 0.5 0.6 0.4 0.0007
Atypical pathogens, %
Mycoplasma pneumoniae < 0.1 < 0.1 0.1 0.0839
Legionella spp. 0.1 0.2 0.1 0.2029
Chlamydia spp. < 0.1 <0.1 < 0.1 0.7561
Anaerobes, % 0.1 0.1 0.1 0.0139
MRSA Methicillin-resistant Staphylococcus aureus
* Comparison between “MRSA therapy” versus “no MRSA therapy” groups
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risk group (15 % versus 9 %; p <0.0001), but lower in the
high-risk group (40 % versus 58 %; p <0.0001) (Fig. 2).
After adjustment for potential confounders, MRSA ther-
apy was associated with higher 30-day mortality in the
low-risk group (aOR 1.47; 95 % CI 1.37–1.58) and lower
30-day mortality in the high-risk group (aOR 0.57; 95 %
CI 0.42–0.77) (Fig. 2).
More than 40 characteristics were compared among
patients who survived and those who died within 30-days
of hospital discharge (Table 4). The multivariable regres-
sion analysis revealed that several of those variables were
independently associated with 30-day mortality (Table 5).
Risk factors varied for low, medium, and high-risk groups.
Discussion
CO-MRSA pneumonia is an evolving problem, and clini-
cians need strategies to determine appropriate candidates
for empiric MRSA therapy. Shorr et al. developed a risk
score to specifically identify CO-pneumonia patients at
risk for MRSA infection [14]. Using a MRSA risk score
similar to Shorr et al., our study demonstrates a survival
advantage for CO-pneumonia among high-risk patients
who received initial MRSA therapy. The number needed
to treat with initial MRSA therapy to save one life in the
high-risk group was 5. This survival advantage was not
present for patients in the low and medium-risk groups.
Our study also supports the notion that the MRSA risk
score might be a better alternative to guide empiric MRSA
therapy in patients with CO-pneumonia as compared to
the HCAP criteria. Several studies have demonstrated that
the HCAP criteria have low specificity for MRSA pneumo-
nia, and that grouping risk factors for MRSA with other
gram-negative MDR pathogens may lead to inappropriate
treatment [11, 22–25]. Recently, Chalmers et al. conducted
a meta-analysis of 24 studies that compared HCAP and
CAP cohorts. The study concluded that the ability for the
HCAP criteria to appropriately identify patients with MDR
pathogens (including MRSA) was low and did not meet
Fig. 1 Unadjusted 30-day patient mortality by MRSA risk score. MRSA Methicillin-resistant Staphylococcus aureus
Fig. 2 30-day patient mortality by MRSA risk score and MRSA therapy. aOR Adjusted Odds Ratio, 95 % CI 95 % Confidence Interval, MRSA
Methicillin-resistant Staphylococcus aureus
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Table 4 Baseline characteristics grouped by 30-day patient mortality
Overall (n = 80,330) 30-day mortality (n = 15,909) No 30-day mortality (n = 64,421) P-value*
Patient age (years), median (IQR) 78 (72–83) 79 (74–84) 77 (72–82) < 0.0001
Male, % 98.3 98.5 98.2 0.0100
Race, %
White 81.1 77.3 82.0 < 0.0001
Black 13.1 14.9 12.6 < 0.0001
Other 5.8 7.8 5.3 < 0.0001
Hispanic ethnicity, % 7.0 7.9 6.8 < 0.0001
MRSA risk score variables, % (1 point, unless noted)
Age >79 43.8 51.0 42.0 < 0.0001
Hospitalization in the past 90 days (2 points) 27.8 40.7 24.7 < 0.0001
Intensive care unit admission (2 points) 21.1 42.0 16.0 < 0.0001
Outpatient IV antibiotic therapy in past 90 days 4.9 6.0 4.7 < 0.0001
Nursing home resident in last 90 days 1.0 0.8 1.0 0.0292
Cerebrovascular disease 18.1 20.0 17.7 < 0.0001
Dementia 5.2 6.7 4.9 < 0.0001
Female with diabetes mellitus 0.4 0.4 0.4 0.8881
MRSA risk score, median (IQR) 1 (0–3) 2 (1–2) 1 (0–2) < 0.0001
Low (0–1), % 51.4 28.4 57.1 < 0.0001
Medium (2–5), % 47.3 68.4 42.1 < 0.0001
High (6–10), % 1.3 3.25 0.9 < 0.0001
Charlson comorbidity score, median (IQR) 2 (1–4) 3 (1–5) 2 (1–4) < 0.0001
Comorbid conditions, %
Myocardial infarction 7.3 8.7 6.9 < 0.0001
Heart failure 25.9 28.2 25.4 < 0.0001
Chronic obstructive pulmonary disease 48.7 41.7 50.4 < 0.0001
Liver disease 1.3 2.3 1.1 < 0.0001
Renal disease 14.1 16.7 13.4 < 0.0001
Diabetes 30.5 30.3 30.5 0.5493
Neoplastic disease 25.2 31.1 23.8 < 0.0001
HIV/AIDS 0.2 0.2 0.2 0.2145
Medication use within 90 days, %
Cardiovascular medications 66.5 60.0 68.0 <0.0001
Anti-diabetic medications 22.2 20.0 22.8 <0.0001
Inhaled corticosteroids 21.1 14.8 22.7 <0.0001
Systemic corticosteroidsa 22.2 21.1 22.5 0.0002
Pulmonary medications 34.8 27.8 36.6 < 0.0001
Vasopressors, % 10.2 26.9 6.0 < 0.0001
Invasive mechanical ventilation, % 11.1 26.8 7.3 < 0.0001
Noninvasive mechanical ventilation, % 4.0 7.1 3.3 < 0.0001
Hemodialysis, % 18.3 23.5 17.0 < 0.0001
Organ failure, %
Any organ failure, % 32.2 57.8 25.9 < 0.0001
Respiratory 14.4 32.6 9.9 < 0.0001
Cardiovascular 9.7 22.1 6.7 < 0.0001
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the threshold for clinical use [26]. In addition, most stud-
ies evaluating the utility of HCAP criteria to guide
broad-spectrum therapy, including MRSA therapy, have
not demonstrated improved mortality with guideline-
concordant therapy [12, 13]. In a large Canadian cohort
study, Grenier et al. were unable to demonstrate a 30-day
mortality benefit in HCAP patients treated with guideline-
concordant antimicrobials [13]. In 2012, Madaras-Kelly et
al. evaluated guideline-endorsed HCAP regimens by
stratifying patients based on risk for MDR pathogens [27].
This study demonstrated that patients who were at higher
risk for MDR pathogens had a survival benefit if they were
treated with guideline-endorsed therapies; however, those
with low risk for MDR pathogens who received guideline-
endorsed therapies had significantly higher mortality.
One advantage of the MRSA risk score is weighting
of important risk factors. The MRSA risk score assigns
more weight (2 points each) to patients with recent
hospitalization and severe pneumonia requiring ICU ad-
mission compared to the other risk factors (1 point each).
In a recent study stratifying risk factors for MDR patho-
gens in CO-pneumonia patients, recent hospitalization
and severe pneumonia were found to be independent
predictors of mortality [28]. This highlights a key fea-
ture of the MRSA risk score, because patients with ei-
ther of those two risk factors cannot be classified into
the low-risk group.
Recently, Minejima et al. compared a smaller cohort of
CO-pneumonia patients with culture-proven MRSA pneu-
monia and non-MRSA pneumonia. They found 37 % of
patients with non-MRSA pneumonia met HCAP criteria
and 28 % received unnecessary MRSA therapy. Had the
MRSA risk score been applied, unwarranted MRSA ther-
apy could have been decreased by 20 % in low-risk patients
without MRSA pneumonia [29]. Our findings further
support the idea that the new MRSA risk score can help
identify low-risk CO-pneumonia patients who are unlikely
to benefit from empiric MRSA therapy.
Our study has important limitations. First, prior studies
have identified risk factors associated with CO-MRSA
pneumonia that were not included in the MRSA risk
score. These include: MRSA infection in the past year,
known MRSA colonization, necrotizing or cavitary pneu-
monia, severity-of-illness scores, and preceding or concur-
rent influenza [19, 29–36]. Similarly, there are patient and
provider characteristics that were not included in our ana-
lyses that might affect patient outcomes. These include spe-
cific antimicrobial medications received, non-antimicrobial
medications, pathogens, antimicrobial susceptibilities, pa-
tient functional status and clinical presentation, and pro-
vider preferences. The study inclusion dates might not
provide a good reflection of current prescribing practices
for CO-pneumonia; however it is important to note that
we sorted the patients into guideline-concordant and dis-
cordant groups according to the recommendations in the
most recent CAP guidelines. We evaluated the impact of
guideline-concordant therapy, pseudomonal therapy, and
atypical therapy in our multivariable models; however, we
did not study specific medications and combinations,
some of which might be associated with better outcomes.
The data source included a predominately elderly male
population. This population had higher 30-day mortality
than that typically seen in non-VA populations, which
could limit the generalizability of our results. In addition,
the older age of the population precluded our ability to
assess Shorr’s MRSA risk criteria for age <30 years. Other
changes in our variable definitions might also have af-
fected outcomes. We altered the prior IV antibiotic use
criteria to include use in the prior 90 days, rather than
30 days. This is likely to result in a larger proportion of
patients who meet this criterion, and might bias the popu-
lation to higher MRSA risk scores.
ICD-9-CM codes were used to identify pneumonia pa-
tients, pathogens, and baseline characteristics. This ap-
proach could potentially lead to misclassification bias, or
underestimate the true prevalence of the pathogens, and
Table 4 Baseline characteristics grouped by 30-day patient mortality (Continued)
Neurological 2.5 4.2 2.0 < 0.0001
Renal 20.1 35.3 16.3 < 0.0001
Hematologic 4.1 8.3 3.0 < 0.0001
Hepatic 0.7 2.0 0.3 < 0.0001
Antibiotic therapy, %
MRSA therapy 36.4 42.9 34.8 < 0.0001
Guideline-concordant CAP therapy 64.1 38.6 70.4 < 0.0001
Pseudomonal therapy 17.5 23.8 15.9 < 0.0001
Atypical therapy 75.2 54.3 80.4 < 0.0001
MRSA Methicillin-resistant Staphylococcus aureus, IQR Interquartile range, IV Intravenous, HIV/AIDS Human immunodeficiency virus/acquired immunodeficiency syn-
drome, CAP Community-acquired pneumonia
aIncludes oral and/or injectable corticosteroids
*Comparison between “30-day mortality” versus “no 30-day mortality” groups
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cannot be considered equivalent to a medical chart review.
There was no MRSA pneumonia code during the time
these patients were treated for pneumonia; therefore,
MRSA pneumonia was defined as a patient with a pneu-
monia ICD-9 code plus a general MRSA ICD-9 code that
was not specific for MRSA pneumonia. Because of this,
the general MRSA code could represent some other infec-
tious process occurring simultaneously with pneumonia
and not necessarily MRSA pneumonia. Furthermore, the
V09.0 code is an imprecise way to identify MRSA
infections, in general [37]. However, there is evidence to
suggest that the code more accurately identifies MRSA
infections in community-onset patients (like the ones
in this study) than in hospital-onset patients [38]. In
the absence of a single code that couples disease with
pathogen, many large databases, like ours, rely on exist-
ing ICD9 codes, like the V09.0 MRSA code plus pneu-
monia codes, for case definitions. A published study
from another group [39], and one from our own group
[40], demonstrate examples where investigators have
Table 5 Risk factors for 30-day patient mortality grouped by MRSA risk score
Adjusted Odds ratio (95 % confidence interval)
Risk score All (n = 80,330) 0–1 (n = 41,282) 2–5 (n = 37,975) 6–10 (n = 1,073)
MRSA therapy 1.22 (1.17-1.27) 1.47 (1.37-1.58) 1.05 (1.00-1.11) 0.57 (0.42-0.77)
Age (1-year increments) 1.05 (1.04-1.05) 1.05 (1.05-1.06) 1.04 (1.03-1.04) 1.05 (1.02-1.08)
Race 0.99 (0.94-1.05) 0.95 (0.86-1.06) 0.98 (0.91-1.05) 1.18 (0.85-1.64)
Hispanic ethnicity 0.85 (0.79-0.92) 0.84 (0.73-0.96) 0.86 (0.79-0.95) 0.79 (0.47-1.32)
Comorbid conditions
Myocardial infarction 1.14 (1.06-1.23) 1.11 (0.94-1.30) 1.05 (0.97-1.14) 1.06 (0.74-1.51)
Heart failure 1.16 (1.11-1.21) 1.07 (0.97-1.17) 1.11 (1.05-1.18) 1.16 (0.88-1.53)
COPD 0.96 (0.91-1.00) 0.92 (0.85-1.00) 0.95 (0.89-1.01) 1.30 (0.96-1.77)
Liver disease 1.79 (1.54-2.08) 1.34 (0.97-1.87) 1.80 (1.50-2.14) 3.46 (1.08-13.51)
Renal disease 0.98 (0.93-1.04) 0.91 (0.81-1.02) 0.96 (0.90-1.03) 1.12 (0.83-1.53)
Neoplastic disease 1.54 (1.47-1.60) 1.57 (1.46-1.69) 1.48 (1.40-1.56) 1.18 (0.87-1.59)
Medication use, by class
Cardiovascular medications 0.72 (0.69-0.75) 0.60 (0.56-0.64) 0.78 (0.73-0.82) 0.91 (0.66-1.24)
Anti-diabetic medications 0.92 (0.87-0.96) 0.78 (0.71-0.86) 0.95 (0.90-1.01) 0.95 (0.70-1.29)
Inhaled corticosteroids 0.76 (0.72-0.81) 0.73 (0.65-0.81) 0.80 (0.74-0.86) 1.13 (0.77-1.65)
Pulmonary medications 1.00 (0.94-1.05) 0.93 (0.85-1.03) 1.03 (0.97-1.11) 0.68 (0.48-0.97)
Vasopressors 1.81 (1.70-1.93) 3.00 (2.49-3.61) 1.66 (1.55-1.79) 1.52 (1.12-2.04)
Mechanical ventilation
Invasive 1.08 (1.01-1.16) 2.48 (1.98-3.10) 1.02 (0.95-1.10) 0.92 (0.65-1.29)
Noninvasive 1.16 (1.06-1.27) 2.03 (1.60-2.57) 1.03 (0.94-1.13) 1.22 (0.80-1.86)
Organ failure
Respiratory 2.48 (2.34-2.63) 3.84 (3.45-4.29) 2.03 (1.90-2.18) 1.47 (1.06-2.04)
Cardiovascular 1.91 (1.80-2.02) 1.90 (1.68-2.15) 1.81 (1.69-1.94) 1.36 (1.02-1.82)
Neurological 1.53 (1.38-1.71) 1.64 (1.33-2.02) 1.40 (1.23-1.58) 1.92 (1.03-3.65)
Renal 1.58 (1.51-1.66) 1.77 (1.62-1.94) 1.46 (1.38-1.55) 1.15 (0.87-1.51)
Hematologic 1.65 (1.52-1.80) 1.97 (1.67-2.32) 1.53 (1.39-1.69) 1.18 (0.73-1.90)
Hepatic 2.54 (2.08-3.11) 3.21 (2.05-5.00) 2.38 (1.90-2.99) 0.66 (0.20-2.16)
Antibiotic therapy
GC-CAP therapy 0.67 (0.63-0.70) 0.60 (0.54-0.67) 0.73 (0.69-0.79) 0.73 (0.50-1.08)
Pseudomonal therapy 1.25 (1.19-1.32) 1.68 (1.53-1.85) 1.05 (0.99-1.12) 0.76 (0.54-1.06)
Atypical therapy 0.45 (0.43-0.48) 0.59 (0.53-0.66) 0.46 (0.43-0.49) 0.75 (0.52-1.08)
MRSA culture positivity 0.66 (0.59-0.74) 0.58 (0.45-0.73) 0.66 (0.58-0.75) 0.56 (0.31-0.99)
Bold indicates statistical significance; MRSA Methicillin-resistant Staphylococcus aureus; Race was ordered as black versus nonblack; COPD Chronic obstructive
pulmonary disease, GC-CAP Guideline-concordant community-acquired pneumonia
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used the V09.0 code to identify patients with MRSA
infections.
Also, it is possible that patients in the MRSA low-risk
group did worse because of the greater prevalence of some
other problem pathogen, for which anti-MRSA antibiotics
have no activity. Reliance on ICD-9 codes for pathogen
identification resulted in a lower rate of pathogen identifi-
cation, so this is not the best study design to identify prob-
lem pathogens. Since this is an observational study, the
impact of MRSA therapy would be better assessed if the
propensity score of MRSA therapy was adjusted for in the
analysis, so that the bias due to observed confounding
(baseline covariates that were associated with MRSA use)
could be minimized. Also, for unobserved confounding,
an instrumental variable approach would further reduce
the bias due to unobserved confounding. However, our
analyses did not consider the propensity score nor instru-
mental variable adjustments due to the limited baseline
data available from the electronic medical record database
and lack of a credible instrumental variable that can be
identified in the literature.
Conclusions
This study demonstrated improved survival with initial
MRSA therapy in high-risk CO-pneumonia patients. The
MRSA risk score might help spare MRSA therapy for only
those patients who are likely to benefit.
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